Isomorphic Labs Entered Phase 2 Trials and AI Drug Discovery Has Crossed the Clinical Validation Threshold
Isomorphic Labs, the drug discovery company spun out of Google DeepMind in 2021, announced in June 2026 that its first wholly AI-designed small molecule drug candidate has advanced to Phase 2 clinical trials — the first time an AI system has independently designed a drug compound that demonstrated sufficient efficacy and safety signals in Phase 1 to advance to the larger patient cohort required for Phase 2 dose and efficacy testing. Isomorphic Labs’ research disclosures describe the compound as targeting a protein-protein interaction in an oncology indication — a class of drug targets historically considered undruggable by conventional medicinal chemistry because their binding surfaces are too flat and featureless for traditional small molecule design. Isomorphic’s approach used AlphaFold 3’s protein structure prediction capabilities combined with its proprietary generative chemistry platform to design compounds that exploit binding pockets that only become visible when the target protein is modeled in its dynamic, multiple-conformation state rather than its most stable crystal structure — a computational advantage that human medicinal chemists approximated through intuition and iterative synthesis but that AI can enumerate systematically at scale. The Phase 1 data showed a favorable safety profile and preliminary pharmacodynamic activity in tumor biomarkers at doses consistent with therapeutic efficacy, which was sufficient to trigger the pre-agreed Phase 2 advancement protocol. Research comparing AI agents to human scientists in research settings has generally found AI systems excel at systematic enumeration of known solution spaces — exactly the kind of combinatorial structure-activity relationship exploration that AI-designed drug discovery relies on — while human scientists contribute more value in identifying the correct problem framing in the first place, which aligns with the hybrid model Isomorphic Labs uses: AI for candidate generation and optimization, human scientists for target selection and clinical strategy.
The pharmaceutical industry’s response to Isomorphic’s Phase 2 announcement reflects the sector’s transition from skepticism to cautious engagement with AI-first drug discovery. Isomorphic Labs disclosed partnership agreements with Eli Lilly and Novartis in 2024 covering multiple discovery programs with combined upfront and milestone payments exceeding $3 billion — transactions that represented a high-risk bet by two major pharmaceutical companies on AI discovery capabilities before any candidate had reached clinical trials. The Phase 2 advancement validates those bets and accelerates the expansion of similar partnership structures across the industry: AstraZeneca, Pfizer, and Roche have each announced expanded AI discovery partnerships with different AI drug development companies in 2025-2026, collectively committing more than $8 billion in partnership value to AI-assisted and AI-first discovery programs. The distinction between AI-assisted and AI-first matters for understanding what the Isomorphic milestone represents: AI-assisted drug discovery (using AI tools to accelerate human-directed discovery campaigns) has been practiced in major pharma for over a decade, with limited but real productivity improvements in screening throughput and molecular property prediction. AI-first discovery — where the AI system generates the initial compound class without human medicinal chemistry intuition guiding the starting point — represents a more radical thesis about how to improve discovery productivity, and Isomorphic’s Phase 2 data is the first clinical validation of that thesis at any scale. The $700 billion AI infrastructure commitment from major technology companies includes significant allocations to AI in life sciences — both through direct investments in drug discovery companies and through cloud computing contracts with pharmaceutical companies expanding their computational biology infrastructure.
What AlphaFold 3 Changed About the Drug Discovery Input Problem
Drug discovery depends on understanding how small molecules interact with target proteins — a problem that requires accurate three-dimensional protein structure models before candidate design can begin. Before AlphaFold 2’s 2021 publication and AlphaFold 3’s 2024 expansion to protein-ligand and protein-protein complexes, pharmaceutical companies relied on X-ray crystallography and cryo-electron microscopy to obtain experimental protein structures — techniques that are accurate but expensive, slow (months per structure), and limited in their ability to capture the full conformational flexibility of dynamic proteins. AlphaFold 3 extended structure prediction from single proteins to protein-ligand complexes (how a drug molecule would bind to a target protein), DNA-protein complexes, and RNA structures — expanding the computational toolkit for drug design beyond what experimental structure determination could practically cover. Isomorphic Labs has exclusive commercial rights to the full AlphaFold technology suite, giving it a structural biology capability advantage over competitors that rely on AlphaFold’s publicly released research models (which are several generations behind the commercial implementation). Recursion Pharmaceuticals, Exscientia (which merged with Recursion in 2024), Absci, and Insilico Medicine all use protein structure prediction in their platforms, but none have the direct access to the latest AlphaFold commercial models that Isomorphic’s DeepMind relationship provides. Nature Drug Discovery’s research coverage through 2025-2026 documents the transformation in structure-based drug design that AlphaFold 3 has enabled — with several peer-reviewed studies demonstrating that AI-predicted protein-ligand binding poses now match experimental crystal structures in accuracy at a rate sufficient to inform lead optimization without experimental confirmation for a meaningful fraction of targets, reducing the experimental iteration cycles that historically consumed two to four years of a drug program’s timeline.
How the AI Drug Discovery Market Is Structured in 2026
The AI drug discovery market has stratified into three distinct models that differ in their integration with pharmaceutical company workflows and in their claim on drug discovery economics. The platform-as-a-service model — exemplified by Schrödinger and OpenEye (now part of Cadence Design Systems) — provides computational chemistry software tools that pharma scientists use as productivity amplifiers within existing discovery workflows, with the pharma company retaining full ownership of discoveries and the software company earning recurring subscription revenue. The partnership model — exemplified by Isomorphic Labs, Exscientia before its merger, and Recursion Pharmaceuticals — involves the AI company co-owning drug candidates generated through its platform in exchange for contributing its computational capabilities to programs co-designed with the pharma partner, with milestone and royalty payments providing the AI company’s return if candidates advance. The fully integrated model — where the AI company owns and develops its own independent pipeline without pharma partnership, as Insilico Medicine has pursued — requires the AI company to bear the full clinical development cost but captures the full economics of successful drugs. Isomorphic Labs operates primarily in the partnership model, but the Phase 2 advancement in its own pipeline (a program Isomorphic owns independently, not through a pharma partnership) signals the company’s intention to build an integrated capability that captures more of the value chain as clinical data accumulates. Enterprise AI deployment at institutional scale across professional services demonstrates that AI systems capable of handling expert-level task complexity at volume — the same characteristic that AlphaFold 3 represents in protein structure prediction — create compound advantages that accumulate as each deployment generates proprietary data that improves subsequent performance.
What the Clinical Validation Threshold Means for AI Discovery Investment
Isomorphic’s Phase 2 entry is commercially significant less for its immediate revenue implications — Phase 2 milestones from pharma partnerships are material but not transformative for a well-funded private company — than for what it signals to pharmaceutical company boards and R&D allocations. The pharmaceutical industry’s productivity crisis is well-documented: the cost to bring a new drug from discovery to approval has increased from approximately $1 billion in the 1990s to an estimated $2.6 billion average in 2024 (in 2024 dollars), driven primarily by late-stage clinical failure rates that have not meaningfully improved despite decades of process optimization. AI-first discovery’s thesis is not that it will eliminate late-stage failure — many Phase 2 failures reflect biological hypotheses about disease mechanisms that no computational tool can validate without clinical data — but that it will reduce the time and cost from discovery to first clinical signal sufficiently to allow more programs to be initiated and tested for the same budget. If Isomorphic’s Phase 2 program demonstrates efficacy in its primary endpoint, it will constitute proof that AI-designed molecules can identify patient populations that respond to a novel mechanism — the biological validation step that the field has been waiting for since AlphaFold 2 proved the structural prediction thesis in 2021. The investment implications are substantial: venture funding for AI drug discovery companies reached $8.4 billion globally in 2025 (according to Pitchbook data covering the sector), with deal size and valuations increasing sharply in Q1-Q2 2026 as Isomorphic’s Phase 2 entry approached public disclosure. Financial Times pharmaceutical coverage through June 2026 positions Isomorphic’s clinical advancement as the inflection point that separates the pre-validation and post-validation eras of AI drug discovery — a transition that will likely reshape how pharmaceutical companies allocate their R&D budgets between internal traditional discovery teams and external AI-first partnerships over the next three to five years, in a pattern similar to how cloud computing adoption reshaped enterprise software procurement between 2012 and 2018.
What Phase 2 Means for the Researchers Who Have Been Waiting for This
The AI drug discovery milestone story is usually told in investment terms: TAM expansion, FDA pathway economics, capital efficiency per approved molecule. That framing is accurate for investors evaluating the sector. It misses the audience that will determine whether AI drug discovery becomes a durable institutional practice over the next decade — the researchers themselves.
Computational biologists, medicinal chemists, and rare-disease patient advocates have spent careers working inside a discovery process whose fundamental constraint was time. A conventional small-molecule program from target identification to Phase 2 entry takes roughly six to nine years, most of which is consumed by iterative synthesis cycles that test structural modifications that experienced chemists suspect won’t work but have to confirm anyway. AlphaFold 3 and the generation of AI-native discovery tools that followed it changed the cost of that iteration — not by making experimental chemistry faster, but by narrowing the space of structures worth synthesizing to those with predicted binding affinity and selectivity profiles above a threshold that justifies lab time. What Isomorphic Labs’ Phase 2 entry represents for those researchers is the first clinical-stage evidence that the narrowing worked: that a drug candidate found through AI-directed structural prediction survived the experimental chemistry step, the toxicology step, and Phase 1 safety assessment well enough to enter a human efficacy trial.
That shift in what researchers believe is possible changes several institutional dynamics before a single commercial product is approved. PhD programs in computational chemistry and structural biology are already seeing application growth from students who want to work at the boundary between AI prediction and wet-lab validation — the Phase 2 data point gives those students a clearer story of where the work leads. Drug company partnership structures are being renegotiated as pharma businesses try to lock in access to AI-native discovery pipelines before Phase 3 data sets a new market price on the capability. And rare-disease advocacy organizations, which have historically focused on regulatory pathway acceleration for drugs that already existed in preclinical development, are beginning to engage earlier — at the discovery stage — because the Phase 2 milestone demonstrated that AI can find candidates in disease areas where conventional chemistry programs had exhausted the obvious structural space. The investment story is important. The researcher story is what determines whether this is a durable change in how medicine is discovered.
What the Dots from Protein Structure to Phase 2 Reveal About How Scientific Breakthroughs Arrive
Steve Jobs’s 2005 Stanford commencement address built its central insight around a single observation: you cannot connect the dots looking forward — you can only connect them looking backward. The path from AlphaFold to Isomorphic Labs’ Phase 2 clinical trial is a case study in what that principle looks like when applied to a scientific breakthrough that is not yet complete but whose trajectory, looking backward, reveals a coherence that was not visible at each individual decision point.
Looking backward from the June 2026 Phase 2 announcement, the dots are: DeepMind’s protein folding problem definition in 2018 (before CASP13 where AlphaFold 1 demonstrated the approach was viable at all); AlphaFold 2’s 2021 Nature publication that essentially solved single-protein structure prediction; the decision to spin Isomorphic Labs out of DeepMind in 2021 as a separate commercial entity with exclusive AlphaFold rights in drug discovery; AlphaFold 3’s 2024 extension to protein-ligand complexes — the step that made AI-designed drug candidates structurally plausible rather than theoretically interesting; and the Phase 2 entry that validates target selection, compound design, and Phase 1 safety in a single clinical program. Each dot was a genuine uncertainty when it was placed. No one in 2018 knew AlphaFold 2 was eighteen months away. No one in 2021 knew AlphaFold 3 would extend to ligand complexes with the accuracy needed for lead optimization. The path from protein structure prediction to clinical drug discovery was visible as a distant possibility; it was not visible as a near-term reality until each subsequent dot was placed and held.
What the dots-backward view reveals about Isomorphic’s Phase 2 milestone is that the hard part was not the drug discovery — it was the series of scientific bets made when the destination was genuinely unknown. Demis Hassabis’s decision to define AlphaFold as a protein structure prediction system rather than a general bioinformatics tool was a dot placed without knowing where it led. The Isomorphic spin-out was a dot placed when the commercial application was entirely unproven. The Eli Lilly and Novartis partnership agreements were dots placed when no AI-designed molecule had entered clinical trials. From 2026, looking backward, the dots form a line. From 2018, looking forward, they did not. The Phase 2 milestone is not where the story started; it is where the earlier dots became legible as a coherent path. The pharmaceutical companies now renegotiating AI discovery partnerships are connecting the same dots — looking backward at Isomorphic’s timeline and inferring what the forward trajectory requires them to commit to before the next Phase 2 milestone is announced by a competitor who moved earlier.
